跳至主要内容
临床试验/NCT07234318
NCT07234318已完成不适用

A Non-interventional Study to Evaluate the Anti-inflammatory Effects and the Clinical Efficacy of Topical Water Free Cyclosporin 0.1% Eye Drops in Patients With Dry Eye Disease and Associated Ocular Surface Inflammation Non-responding to Artificial Tears: the FOCUS Study

Laboratoires Thea1 个研究点 分布在 1 个国家目标入组 25 人开始时间: 2026年1月20日最近更新:
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
25
试验地点
1
主要终点
Dryness score assessed by a VAS and Conjunctival hyperemia grading with Photographs (Efron) scale at week 12

研究概览

简要总结

The FOCUS study aims to evaluate the clinical efficacy of 0.1% cyclosporine eye drops solution (Vevizye®, Laboratoires THEA) in patients with moderate to severe dry eye disease characterized by ocular surface inflammation.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Age ≥ 18 years
  • No patients with other ophthalmic diseases than DED
  • Chronic dry eye defined as longer than six months since diagnosis
  • OSDI score > 22
  • Conjunctival Hyperemia ≥ Grade 3 (Efron Scale)
  • Current use of tear substitutes for at least 3 months not to be considered as sufficient by the investigator/treating physician
  • Need to add cyclosporine eye drops to tear substitutes as judged by the investigator/treating physician

排除标准

  • Ophthalmic exclusion criteria
  • Far best corrected visual acuity < 1/10
  • Severe Dry Eye associated with:
  • Eyelid malposition
  • Stevens Johnson Syndrome
  • Corneal dystrophy
  • Ocular neoplasia
  • Filamentous keratitis
  • Corneal neovascularisation
  • Orbital radiotherapy
  • Dry eye related to Graft Versus Host Disease (GVHD)
  • History of any of the following within last 3 months:
  • Systemic treatment of dry eye
  • Systemic treatment of Meibomian Gland Dysfunction (MGD)
  • Isotretinoïde,
  • Cyclosporine,
  • Tacrolimus, Siromilus, Pimecrolimus
  • Punctual plugs
  • History of any of the following within previous six months:
  • ocular trauma
  • ocular infection, Ocular allergy
  • History of any of the following within last 12 months:
  • inflammatory corneal ulcer
  • Herpetic eye infection
  • or uveitis
  • Ocular surgery
  • Systemic / non ophthalmic exclusion criteria:
  • Known hypersensitivity to any of the components of the medical product under investigation or other study medication
  • Specific exclusion criteria for women:
  • Pregnant or breast-feeding woman.
  • Woman of childbearing potential (neither menopausal, nor hysterectomized, nor sterilized) not using effective contraception (i.e. hormonal contraceptives, intra-uterine device, contraceptive implant or condoms with spermicide)
  • Exclusion criteria related to general conditions
  • Inability of patient to understand the investigation procedures and thus inability to give valid, informed consent.
  • Non-compliant patient (e.g. not willing to attend the follow-up visits, way of life interfering with compliance)
  • Participation in another clinical study or clinical investigation at the same time as the present investigation
  • Participation to the present clinical investigation during the exclusion period of another clinical study
  • Patient already included once in this clinical investigation
  • Patient under guardianship

结局指标

主要结局

Dryness score assessed by a VAS and Conjunctival hyperemia grading with Photographs (Efron) scale at week 12

时间窗: at week 12 versus baseline

Scores will be determined using a 100 mm VAS on which 0 means "no feeling of eye dryness" and 100 means "most imaginable feeling of eye dryness".

次要结局

未报告次要终点

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验